C (N T R U M

Satin Creditcare Network

Weak AuM growth, provisions a key monitorable

Satin results were a miss on AuM growth (+14% YoY vs est. of 22%) though NII beat was led by NIM expansion. Disbursements/repayments were lower/higher to est. by 11%/10%. Opex downtick and assignment income protected PPoP which was in line at Rs1.07bn. Provisions almost tripled sequentially to Rs529mn driven by stress in upper Assam and demonetisation related write-offs. CE in Assam is improving (at 75-80% vs 50% in Nov'19). We see AuM growth to pick-up in FY21/22E to 25%. RoA/RoE is set to come in at 2.6%/19.4% in FY22E. Valuation at 0.6x is attractive. Roll forward to FY22E ABV, retain Buy but revise multiple/TP to 1.0x/Rs300 (1.5x/Rs410 earlier).

Q3FY20 results - Weak on AuM, PPOP in-line, provisions spike

NII at Rs1.3bn saw a QoQ uptick (beating est. by 13%) driven by reported QoQ NIM expansion of 54bps QoQ to 12.9%. There was a QoQ yield/cost improvement of 26b/27bps. AuM growth was a miss at +14.3% YoY (est. 21% YoY) to Rs63.9bn. Disbursements were lower to est. by 11% and repayments were higher by 10%. Assignment income at Rs556mn, again contributed a chunk to other income. Opex was slightly lower due to other expenses and PPoP was in line at Rs1.1bn. GNPA ratio was stable QoQ at 3.1% while ECL came in higher at 2.2% vs 1.7% QoQ as provisions spiked to Rs529mn (est. Rs200mn). Tax expense was lower (tax rate at 13%) due to DTA. Net profit was lower at Rs477mn (est. Rs627mn).

Quarterly lower net accretion to AuM might lead to muted FY20E AuM growth.

Disbursements at Rs19.0bn were lower as due to process improvements, rejection rates rose YoY from 15% to 18%. Also, higher repayments were faster at 30% of opening AuM (vs avg. 25% for the last 8 quarters) as scheduled repayments were concentrated in the Q2&Q3FY20. Usually H2 is stronger for Satin (H2 is ~40% higher than H1) and management interaction suggests that the disbursement pace has picked-up. Factoring in higher net accretion in Q4FY20 AuM, we lower our FY20 AuM growth to 12% YoY (vs 21% earlier). For FY21/22E each we see growth resuming back to 25% AuM growth. Owing to higher liquidity on the balance sheet and lower growth, NIM for FY20E might dip by 60bps YoY to 8.3% (vs est. 8.6% earlier).

Assam portfolio stress and demonetisation related write-offs led to provision spike

Provision spiked sequentially and of the Rs529mn, provisions for the upper Assam portfolio were Rs290mn and write-offs were Rs240mn. Assam stage-3 is Rs30mn which might escalate in Q4FY20. However, upper Assam CE which was 50% in Nov'19 during CAA/NRC protest, has improved to 75-80%. CE for rest of Assam is 99%. Assam exposure is 6.1% though on-book portfolio is Rs2.5bn. The company does not face any challenges in West Bengal (5.6% of GLP). We see provisions to remain elevated in Q4FY20E and raise our provision estimates to 3.1% for FY20E (vs 1.5% earlier). Valuation and risks

For FY20 we have trimmed our NII/AUM and raised our provision est. while for FY21 we increase provisions. FY20E/21E earnings cut is -23.1%/-23.6%. Near term MFI potential is intact but credit costs might be higher. Revise multiple to 1.0x (vs 1.5x earlier) due to the earnings cut, roll forward to FY22 ABV to arrive at a TP of Rs300 (Rs410 earlier). Maintain BUY on attractive valuations. Risks: higher opex and spike in NPA.

Financial and valuation summary

| Q3FY20 | Q3FY19 | YoY (%) | Q2FY20 | QoQ (%) | FY20E | FY21E | FY22E |
|--------|--|--|--|---|---|--|---|
| 1312 | 1356 | (3.2) | 1158 | 13.3 | 5,010 | 5,722 | 7,339 |
| 1079 | 1239 | (12.9) | 904 | 19.4 | 3,858 | 4,342 | 5,483 |
| 529 | 99 | 431.7 | 140 | 277.7 | 1,386 | 1,137 | 1,252 |
| 477 | 700 | (31.9) | 549 | (13.1) | 1,779 | 2,397 | 3,165 |
| 14.3 | 29.9 | (15.6) | 15.3 | (1.0) | 12.0 | 24.9 | 24.7 |
| 12.9 | 15.4 | (2.5) | 12.3 | 0.5 | 8.3 | 8.6 | 8.7 |
| 46.9 | 42.3 | 4.6 | 54.7 | (7.8) | 51.3 | 51.0 | 50.4 |
| 3.1 | 3.2 | 0.1 | 3.1 | 0.0 | 3.6 | 3.3 | 3.1 |
| 2.9 | 4.2 | 1.3 | 3.3 | 0.4 | 2.0 | 2.4 | 2.6 |
| 13.8 | 26.9 | (13.1) | 16.5 | (2.7) | 15.1 | 17.4 | 19.4 |
| - | - | - | - | - | 0.8 | 0.7 | 0.6 |
| | 1312 1079 529 477 14.3 12.9 46.9 3.1 2.9 | 1312 1356 1079 1239 529 99 477 700 14.3 29.9 12.9 15.4 46.9 42.3 3.1 3.2 2.9 4.2 13.8 26.9 | 1312 1356 (3.2) 1079 1239 (12.9) 529 99 431.7 477 700 (31.9) 14.3 29.9 (15.6) 12.9 15.4 (2.5) 46.9 42.3 4.6 3.1 3.2 0.1 2.9 4.2 1.3 13.8 26.9 (13.1) | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |

Source: Company, Centrum Research estimates

Please see Appendix for analyst certifications and all other important disclosures.

Result Update

India I Diversified Financials

20 February 2020

Buy

Target Price: Rs300 Price: Rs181 Forecast return: 66%


Market Data

| Bloomberg: | SATIN IN |
|-----------------------|-----------|
| 52 week H/L: | Rs398/182 |
| Market cap: | Rs10bn |
| Shares outstanding: | 52mn |
| Free float: | 53.5% |
| Avg. daily vol. 3mth: | 143,564 |
| Source: Bloomberg | |

Changes in the report

| Rating: | Unchanged |
|----------------------|---------------------------|
| Target Price: | To Rs300 from Rs410 |
| EPS: | (23)% FY20E & (24)% FY21E |
| Source: Centrum Rese | earch |

SATIN relative to Nifty Midcap 100



Shareholding pattern

| | Dec-19 | Sep-19 | Jun-19 | Mar-19 |
|-------------|--------|--------|--------|--------|
| Promoter | 30.2 | 29.7 | 29.7 | 27.9 |
| FIIs | 7.8 | 13.5 | 13.3 | 14.8 |
| DIIs | 25.3 | 23.2 | 23.9 | 21.7 |
| Public/oth | 36.8 | 33.6 | 33.1 | 35.6 |
| Source: BSE | | | | |



Analyst, Banks, Diversified Financials +91 22 4215 9110 gaurav.jani@centrum.co.in



BFSI

Rahul Nandwani Associate, Banks, Diversified Financials +91 22 4215 9364 rahul.nandwani@centrum.co.in

Thesis Snapshot

Estimate revisions

| YE Mar (Rs mn) | FY20E | FY20E | 0∕aha | FY21E | FY21E | % ah a |
|----------------|-------|-------|--------|-------|-------|--------|
| te Mar (KS mn) | New | Old | % chg | New | Old | % chg |
| NII | 5,010 | 5,339 | (6.2) | 5,722 | 5,950 | (3.8) |
| PPoP | 3,858 | 3,958 | (2.5) | 4,342 | 4,943 | (12.2) |
| PAT | 1,779 | 2,313 | (23.1) | 2,397 | 3,137 | (23.6) |
| AUM growth (%) | 12.0 | 21.4 | (9.4) | 24.9 | 25.2 | (0.3) |
| GNPA | 3.6 | 3.2 | 36bps | 3.3 | 3.1 | 22bps |

Source: Centrum Research estimates

Centrum estimates vs Actual results

| Q3FY20 | Q3FY20 | (0/) |
|--------|-------------|---|
| | 201120 | (%) |
| 1,312 | 1,166 | 12.5 |
| 1079 | 1071 | 0.8 |
| 477 | 627 | (24.0) |
| 14.3 | 21.9 | (7.6) |
| | 1079 477 | 1079 1071 477 627 14.3 21.9 |

Source: Bloomberg, Centrum Research estimates

Satin versus Nifty Midcap 100

| | 1m | 6m | 1 year |
|------------------------|--------|--------|--------|
| SATIN IN | (21.8) | (33.0) | (19.0) |
| Nifty Midcap 100 | 0.9 | 15.3 | 11.2 |
| Source: Bloomberg, NSE | | | |

Key assumptions

| YE Mar (Rs mn) | FY20E | FY21E | FY22E |
|------------------------|-------|-------|-------|
| AUM growth (%) | 12.0 | 24.9 | 24.7 |
| NIM (%) | 8.3 | 8.6 | 8.7 |
| Other inc / Assets (%) | 4.6 | 4.7 | 4.4 |
| Cost / Assets (%) | 6.0 | 5.6 | 5.6 |
| Provision costs | 3.1 | 2.1 | 1.8 |

Source: Centrum Research estimates

Valuations

For FY20 we have trimmed our NII/AUM and raised our provision est. while for FY21 we increase provisions. FY20E/21E earnings cut is -23.1%/-23.6%. Near term MFI potential is intact but credit costs might be higher. Revise multiple to 1.0x (vs 1.5x earlier) due to the earnings cut, roll forward to FY22 ABV to arrive at a TP of Rs300 (Rs410 earlier). Maintain BUY on attractive valuations. Risks: higher opex and spike in NPA.

| valuations | |
|-------------------------|--------|
| FY22E ABVPS (Rs) | 297.9 |
| Historical P/ABV (x) | 2.0 |
| Premium assigned (%) | (50.0) |
| Ascribed P/ABV (x) | 1.0 |
| Fair value / share (Rs) | 300 |



Sensitivity analysis

| | Provision cost | | | | | | | | |
|---------|---------------------------|--|---|---|---|--|--|--|--|
| | +10bps | +5bps | Current | -5bps | -10bps | | | | |
| -10bps | (3.6) | (2.8) | (2.0) | (1.2) | (0.4) | | | | |
| -5bps | (2.6) | (1.8) | (1.0) | (0.2) | 0.6 | | | | |
| Current | (1.6) | (0.8) | 0.0 | 0.8 | 1.6 | | | | |
| +5bps | (0.6) | 0.2 | 1.0 | 1.8 | 2.6 | | | | |
| +10bps | 0.4 | 1.2 | 2.0 | 2.8 | 3.6 | | | | |
| | -5bps Current +5bps | -10bps (3.6) -5bps (2.6) Current (1.6) +5bps (0.6) | +10bps +5bps -10bps (3.6) (2.8) -5bps (2.6) (1.8) Current (1.6) (0.8) +5bps (0.6) 0.2 | +10bps +5bps Current -10bps (3.6) (2.8) (2.0) -5bps (2.6) (1.8) (1.0) Current (1.6) (0.8) 0.0 +5bps (0.6) 0.2 1.0 | +10bps +5bps Current -5bps -10bps (3.6) (2.8) (2.0) (1.2) -5bps (2.6) (1.8) (1.0) (0.2) Current (1.6) (0.8) 0.0 0.8 +5bps (0.6) 0.2 1.0 1.8 | | | | |

Source: Bloomberg, Centrum Research estimates

Peer comparison

| Commony | Mkt Cap | CAGR FY | 19-FY22 | E (%) | | P/B | VPS | | | RoA | . (%) | | | Ro | E (%) | |
|------------------|---------|-----------|---------|-------|------|-------|-------|-------|------|-------|-------|-------|------|-------|-------|-------|
| Company | Rs bn | Total inc | PPOP | PAT | FY19 | FY20E | FY21E | FY22E | FY19 | FY20E | FY21E | FY22E | FY19 | FY20E | FY21E | FY22E |
| Satin CreditCare | 9.4 | 14.6 | 15.3 | 17.5 | 1.3 | 0.7 | 0.6 | 0.6 | 2.6 | 2.0 | 2.4 | 2.6 | 19.1 | 15.1 | 17.4 | 19.4 |
| Ujjivan SFB | 92.2 | 33.18 | 57.9 | 57.5 | 5.0 | 3.1 | 2.6 | 2.2 | 1.7 | 2.1 | 2.5 | 2.7 | 12.9 | 14.6 | 16.3 | 20.1 |
| Equitas | 39.0 | 26.4 | 70.6 | 58.2 | 1.9 | 1.4 | 1.2 | 1.0 | 1.2 | 1.5 | 1.8 | 1.9 | 7.5 | 10.9 | 13.6 | 16.3 |
| Credit Access | 140.6 | 17.4 | 18.8 | 20.9 | 4.5 | 4.3 | 3.5 | 2.8 | 4.1 | 3.4 | 2.8 | 2.9 | 17.0 | 17.3 | 18.8 | 20.2 |
| Spandana | 70.4 | 19.0 | 18.3 | 21.2 | 2.6 | 2.5 | 2.1 | 1.7 | 2.2 | 2.8 | 2.3 | 2.4 | 21.5 | 17.9 | 23.5 | 24.3 |

Fig 1: Key concall takeaways and metrics

| FY20E Guidance | Q3FY20 | Q2FY20 | Our Comments |
|------------------|--------|----------------------------------|--|
| AuM growth | - | 20-25% | Satin had revised its AuM growth guidance to 20-25% in Q2FY20. Given the muted growth seen in Q3FY20 we do not foresee it achieving this target. We see AUM growth of 12.0% for FY20. Over FY19-22E, see an AuM CAGR of 20% over FY19-22E. |
| NIM | - | - | 9MFY20 has seen muted on AuM growth for Satin owing to process rationalisation (leading to higher rejection) and scheduled repayments in the 3-9M maturity bucket. Slower credit off-take and faster repayments have led to higher liquidity on the balance sheet leading to an NIM drag. Hence we revise our FY20 NIM estimate lower to 8.3% (vs 8.6% earlier). As we expect growth to pick-up in FY21/22E we might see NIM improving to 8.6%/8.7%. |
| Opex | - | Opex efficiency to improve | Opex improved in Q3FY20 with cost to income improving to 47.5% QoQ from 54.4%. This was led by higher NII and lower other expenses. Given the branch and employee expansion in 9MFY20 and given that no chunky opex costs are expected we see opex to AuM ratio to improve from 6.0% to 5.6% over FY19-22E. |
| Provisions costs | - | - | Due to the negative surprise in the Assam portfolio, FY20 credit costs might see a spike and we raise our est. to 310bps (vs 150bps earlier). We see provisions to taper down to 210/180bps in FY21/22E. |
| Consol. PAT | - | Rs.2.6bn | Consol. PAT of Rs.2.6bn was guided for FY20. We see a standalone PAT of Rs1.8bn for FY20 as 9MFY20 earnings were marred by a spike in provisions. We see standalone PAT/RoA/RoE at Rs3.2bn/2.6%/19.4% in FY22E. |

Fig 2: Quarterly Financials

| Profit & Loss (Rs mn) | Q4FY18 | Q1FY19 | Q2FY19 | Q3FY19 | Q4FY19 | Q1FY20 | Q2FY20 | Q3FY20 |
|-----------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|
| Interest earned | 2,713 | 3,045 | 3,152 | 3,022 | 2,575 | 2,715 | 2,627 | 2,728 |
| Interest expended | 1,440 | 1,533 | 1,681 | 1,666 | 1,510 | 1,506 | 1,468 | 1,416 |
| Net interest income | 1,273 | 1,512 | 1,472 | 1,356 | 1,065 | 1,209 | 1,158 | 1,312 |
| Other income | 64 | 49 | 316 | 792 | 726 | 614 | 825 | 745 |
| Total income | 1,337 | 1,561 | 1,788 | 2,148 | 1,791 | 1,824 | 1,983 | 2,057 |
| Operating expenses | 714 | 823 | 914 | 909 | 1,065 | 994 | 1,080 | 978 |
| Employees | 474 | 597 | 617 | 703 | 731 | 730 | 761 | 721 |
| Others | 240 | 227 | 298 | 206 | 333 | 265 | 318 | 257 |
| Operating profit | 623 | 738 | 874 | 1,239 | 726 | 829 | 904 | 1,079 |
| Provisions | (2) | 358 | 184 | 99 | (121) | 180 | 140 | 529 |
| Profit before tax | 625 | 380 | 690 | 1,139 | 847 | 649 | 764 | 550 |
| Тах | 213 | 129 | 246 | 439 | 292 | 236 | 215 | 74 |
| Profit after tax | 411 | 250 | 444 | 700 | 555 | 414 | 549 | 477 |
| Balance sheet | | | | | | | | |
| AUM (Rs mn) | 50,848 | 54,002 | 55,612 | 55,900 | 63,740 | 64,670 | 64,140 | 63,900 |
| AUM growth (%) | 40.6 | 43.2 | 39.5 | 29.9 | 25.4 | 19.8 | 15.3 | 14.3 |
| Total CRAR (%) | 23.7 | 26.4 | 25.2 | 30.1 | 28.5 | 30.5 | 30.1 | 32.2 |
| Profitability ratios (reported %) | | | | | | | | |
| Gross yield | 23.7 | 23.6 | 25.7 | 27.4 | 22.1 | 20.7 | 21.4 | 21.7 |
| Financial cost | 12.3 | 11.7 | 12.3 | 12.0 | 10.1 | 9.4 | 9.1 | 8.9 |
| NIM | 11.4 | 11.9 | 13.4 | 15.4 | 12.0 | 11.4 | 12.3 | 12.9 |
| Opex ratio | 6.1 | 6.3 | 6.9 | 6.5 | 7.1 | 6.4 | 6.7 | 6.0 |
| Loan loss ratio | 0.0 | 2.7 | 1.5 | 0.7 | -0.8 | 1.1 | 0.9 | 3.4 |
| ROA | 2.8 | 1.5 | 2.6 | 4.2 | 3.3 | 2.5 | 3.3 | 2.9 |
| Leverage | 5.8 | 5.9 | 5.4 | 5.1 | 4.6 | 3.9 | 3.6 | 3.4 |
| ROE | 18.9 | 10.7 | 18.0 | 26.9 | 20.0 | 13.5 | 16.5 | 13.8 |
| Cost to income | 53.4 | 52.7 | 51.4 | 42.3 | 59.5 | 54.6 | 54.7 | 46.9 |
| Asset quality ratios (%) | | | | | | | | |
| GNPA | 4.4 | 3.9 | 4.1 | 3.2 | 2.9 | 2.8 | 3.1 | 3.1 |
| ECL | 4.2 | 3.5 | 3.2 | 2.0 | 1.6 | 1.6 | 1.7 | 2.2 |

20 February 2020

| P&L (Rs mn) | FY18 | FY19 | FY20E | FY21E | FY22E |
|--------------------|-------|--------|--------|--------|--------|
| Interest income | 9,573 | 11,795 | 10,804 | 11,720 | 15,013 |
| Interest expense | 5,317 | 6,390 | 5,794 | 5,998 | 7,674 |
| NII | 4,256 | 5,405 | 5,010 | 5,722 | 7,339 |
| Other income | 194 | 1,935 | 2,908 | 3,139 | 3,721 |
| Total income | 4,450 | 7,340 | 7,918 | 8,861 | 11,060 |
| Operating expenses | 2,740 | 3,763 | 4,061 | 4,519 | 5,577 |
| Employee | 1,892 | 2,648 | 2,942 | 3,197 | 3,832 |
| Others | 848 | 1,115 | 1,118 | 1,322 | 1,745 |
| РРОР | 1,711 | 3,577 | 3,858 | 4,342 | 5,483 |
| Provisions | 445 | 521 | 1,386 | 1,137 | 1,252 |
| РВТ | 1,266 | 3,056 | 2,471 | 3,205 | 4,231 |
| Tax | 445 | 1,107 | 692 | 808 | 1,066 |
| РАТ | 821 | 1,949 | 1,779 | 2,397 | 3,165 |
| Ratios | FY18 | FY19 | FY20E | FY21E | FY22E |

| Ratios | FY18 | FY19 | FY20E | FY21E | FY22E |
|-----------------------------|--------|-------|--------|--------|-------|
| Growth (%) | | | | | |
| AUM | 40.6 | 25.3 | 12.0 | 24.9 | 24.7 |
| Borrowings | 14.0 | 9.2 | (14.3) | 24.4 | 32.6 |
| NII | 41.6 | 27.0 | (7.3) | 14.2 | 28.3 |
| Other income | (52.6) | 895.9 | 50.3 | 7.9 | 18.5 |
| Opex | 7.9 | 37.4 | 7.9 | 11.3 | 23.4 |
| РРоР | 95.1 | 109.1 | 7.9 | 12.6 | 26.3 |
| Provisions | (12.0) | 17.1 | 166.2 | (18.0) | 10.1 |
| РАТ | 235.3 | 137.3 | (8.7) | 34.7 | 32.0 |
| Profitability ratios (%) | | | | | |
| Yield on IEA | 18.1 | 19.5 | 17.9 | 17.5 | 17.9 |
| Cost of funds | 13.0 | 14.0 | 13.1 | 13.1 | 13.0 |
| Spread | 5.1 | 5.4 | 4.8 | 4.4 | 4.9 |
| NIM | 8.1 | 8.9 | 8.3 | 8.6 | 8.7 |
| Other Income/ Total Income | 4.4 | 26.4 | 36.7 | 35.4 | 33.6 |
| Other Income / Total Assets | 0.4 | 3.0 | 4.6 | 4.7 | 4.4 |
| Cost / Income | 61.6 | 51.3 | 51.3 | 51.0 | 50.4 |
| Employees | 42.5 | 36.1 | 37.2 | 36.1 | 34.7 |
| Others | 19.1 | 15.2 | 14.1 | 14.9 | 15.8 |
| Opex / AuM | 6.3 | 6.6 | 6.0 | 5.6 | 5.6 |
| Provisions | 1.0 | 1.1 | 3.1 | 2.1 | 1.8 |
| Tax Rate | 35.1 | 36.2 | 28.0 | 25.2 | 25.2 |
| RoA | 1.4 | 2.6 | 2.0 | 2.4 | 2.6 |
| RoE | 12.2 | 19.1 | 15.1 | 17.4 | 19.4 |

| DuPont (% avg assets) | FY18 | FY19 | FY20E | FY21E | FY22E |
|-----------------------|------|------|-------|-------|-------|
| Interest income | 16.4 | 15.6 | 12.3 | 11.8 | 12.3 |
| Interest expense | 9.1 | 8.5 | 6.6 | 6.0 | 6.3 |
| NII | 7.3 | 7.1 | 5.7 | 5.8 | 6.0 |
| Other income | 0.3 | 2.6 | 3.3 | 3.2 | 3.0 |
| Total income | 7.6 | 9.7 | 9.0 | 8.9 | 9.1 |
| Operating expenses | 4.7 | 5.0 | 4.6 | 4.6 | 4.6 |
| Employees | 3.2 | 3.5 | 3.3 | 3.2 | 3.1 |
| Others | 1.5 | 1.5 | 1.3 | 1.3 | 1.4 |
| РРОР | 2.9 | 4.7 | 4.4 | 4.4 | 4.5 |
| Provisions | 0.8 | 0.7 | 1.6 | 1.1 | 1.0 |
| РВТ | 2.2 | 4.0 | 2.8 | 3.2 | 3.5 |
| Тах | 0.8 | 1.5 | 0.8 | 0.8 | 0.9 |
| PAT | 1.4 | 2.6 | 2.0 | 2.4 | 2.6 |

Source: Company, Centrum Research estimates

| Balance Sheet (Rs mn) | FY18 | FY19 | FY20E | FY21E | FY22E |
|---------------------------|--------|--------|--------|--------|--------|
| Financial assets | 61,096 | 66,082 | 58,600 | 73,223 | 93,671 |
| Cash | 4,458 | 10,039 | 6,019 | 6,571 | 6,899 |
| Bank balance | 6,374 | 6,940 | 5,556 | 5,973 | 7,665 |
| Loans | 48,452 | 44,601 | 41,195 | 54,377 | 71,044 |
| Investment | 1,486 | 4,219 | 5,556 | 5,973 | 7,665 |
| Others | 326 | 284 | 274 | 329 | 398 |
| Non-financial assets | 1,530 | 992 | 764 | 986 | 1,265 |
| Deferred tax assets | 887 | 312 | 278 | 418 | 537 |
| Fixed Assets | 360 | 430 | 417 | 448 | 575 |
| Others | 283 | 250 | 69 | 119 | 153 |
| Total Assets | 62,626 | 67,073 | 59,364 | 74,209 | 94,936 |
| Financial liabilities | 53,436 | 55,230 | 46,997 | 58,424 | 77,421 |
| Debt securities | 9,193 | 9,759 | 8,358 | 10,396 | 13,783 |
| Borrowings | 38,624 | 37,200 | 31,862 | 39,628 | 52,540 |
| Subordinated Debt | 3,692 | 5,392 | 4,618 | 5,744 | 7,615 |
| Others | 1,927 | 2,879 | 2,159 | 2,656 | 3,482 |
| Non-financial liabilities | 270 | 329 | 243 | 304 | 389 |
| Current tax liabilities | 91 | 118 | 87 | 109 | 139 |
| Provisions | 102 | 135 | 100 | 125 | 160 |
| Others | 77 | 76 | 56 | 70 | 90 |
| Total equity | 8,919 | 11,514 | 12,123 | 15,481 | 17,126 |
| Share capital | 473 | 485 | 485 | 535 | 535 |
| Other equity | 8,446 | 11,029 | 11,638 | 14,946 | 16,592 |
| Total Liabilities | 62,626 | 67,073 | 59,364 | 74,209 | 94,936 |
| Balance Sheet ratios (%) | | | | | |
| Debt / Equity | 5.8 | 4.5 | 3.7 | 3.6 | 4.3 |
| Assets / Equity | 7.0 | 5.8 | 4.9 | 4.8 | 5.5 |
| Cash / Borrowings | 0.2 | 0.3 | 0.3 | 0.2 | 0.2 |
| Capital (%) | 3,385 | 362 | | | |
| CRAR | 21.2 | 28.5 | 31.2 | 28.6 | 25.6 |
| Tier-1 | 14.6 | 19.9 | 23.1 | 21.1 | 18.9 |
| Tier-2 | 6.6 | 8.6 | 8.6 | 7.4 | 6.7 |
| Asset quality (%) | | | | | |
| GNPA (Rs mn) | 2,152 | 1,779 | 2,539 | 2,956 | 3,490 |
| NNPA (Rs mn) | 742 | 1,061 | 889 | 994 | 1,198 |
| GNPA | 4.2 | 2.8 | 3.6 | 3.3 | 3.1 |
| NNPA | 1.5 | 1.7 | 1.2 | 1.1 | 1.1 |
| PCR | 65.5 | 40.4 | 65.0 | 66.4 | 65.7 |
| NNPA/ Equity | 8.3 | 9.2 | 7.3 | 6.4 | 7.0 |
| Per share (Rs) | | | | | |
| EPS | 17.4 | 40.2 | 36.7 | 44.8 | 59.2 |
| BVPS | 188.7 | 237.3 | 249.8 | 289.5 | 320.3 |
| ABVPS | 173.0 | 215.4 | 231.5 | 270.9 | 297.9 |
| Valuation (x) | | | | | |
| P/E | 20.4 | 7.7 | 5.0 | 4.1 | 3.1 |
| P/BV | 1.9 | 1.3 | 0.7 | 0.6 | 0.6 |
| P/ABV | 2.1 | 1.4 | 0.8 | 0.7 | 0.6 |

Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the fore going limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mr. Gaurav Jani & Mr. Rahul Nandwani, research analyst and and/or any of their family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by them, they are not received any compensation from the above companies in the preceding twelve months. They do not hold any shares by them or through their relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Ratings definitions

Our ratings denote the following 12-month forecast returns:

Buy – The stock is expected to return above 15%.

Add – The stock is expected to return 5-15%.

Reduce – The stock is expected to deliver -5-+5% returns.

Sell – The stock is expected to deliver <-5% returns.

Satin Creditcare



Source: Bloomberg

| | | Disclosure of Interest Statement | | | |
|----|---|--|------------------|--|--|
| 1 | 1 Business activities of Centrum Broking Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivative Limited (CBL) Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI register Portfolio Manager. | | | | |
| 2 | Details of Disciplinary History of CBL | CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in secu | urities market. | | |
| 3 | Registration status of CBL: | CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469) | | | |
| | | | Satin Creditcare | | |
| 4 | Whether Research analyst's or relatives' | have any financial interest in the subject company and nature of such financial interest | No | | |
| 5 | Whether Research analyst or relatives ha immediately preceding the date of public | we actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month cation of the document. | No | | |
| 6 | Whether the research analyst or his relation | ives has any other material conflict of interest | No | | |
| 7 | Whether research analyst has received which such compensation is received | any compensation from the subject company in the past 12 months and nature of products / services for | No | | |
| 8 | Whether the Research Analyst has receiv research report | ved any compensation or any other benefits from the subject company or third party in connection with the | No | | |
| 9 | Whether Research Analysts has served as | s an officer, director or employee of the subject company | No | | |
| 10 | Whether the Research Analyst has been e | engaged in market making activity of the subject company. | No | | |
| 11 | Whether it or its associates have manage | d or co-managed public offering of securities for the subject company in the past twelve months; | No | | |
| 12 | Whether it or its associates have receiv company in the past twelve months; | ed any compensation for investment banking or merchant banking or brokerage services from the subject | No | | |
| 13 | Whether it or its associates have received services from the subject company in the | d any compensation for products or services other than investment banking or merchant banking or brokerage past twelve months; | No | | |

Member (NSE and BSE). Member MSEI (Inactive)

Single SEBI Regn No.: INZ000205331

Depository Participant (DP)

CDSL DP ID: 120 – 12200 SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Research Analyst SEBI Registration No. INH000001469

Mutual Fund Distributor AMFI REGN No. ARN- 147569

Website: www.centrum.co.in Investor Grievance Email ID: investor.grievances@centrum.co.in

Compliance Officer Details:

Ashok D Kadambi (022) 4215 9937; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)

Registered Office Address Bombay Mutual Building , 2nd Floor, Dr. D. N. Road, Fort, Mumbai - 400 001 Corporate Office & Correspondence Address Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai 400 098. Tel: (022) 4215 9000 Fax: +91 22 4215 9344

| | Centrum Broking Institutional Equities Team Details | | | | | | |
|--------------------|---|----------------------------------|------------------|--|--|--|--|
| Nischal Maheshwari | CEO | nischal.maheshwari@centrum.co.in | +91-22-4215 9841 | | | | |
| Research Analyst | Sector | E-mail | Phone number | | | | |
| Sneha Prashant | Auto & Auto Ancillary | sneha.prashant@centrum.co.in | +91-22-4215 9263 | | | | |
| Gaurav Jani | BFSI | gaurav.jani@centrum.co.in | +91-22-4215 9110 | | | | |
| Milind S Raginwar | Cement & Metals | milind.raginwar@centrum.co.in | +91-22-4215 9201 | | | | |
| Shirish Pardeshi | FMCG | shirish.pardeshi@centrum.co.in | +91-22-4215 9634 | | | | |
| Ashish Shah | Infra & Aviation | shah.ashish@centrum.co.in | +91-22-4215 9021 | | | | |
| Madhu Babu | IT | madhu.babu@centrum.co.in | +91-22-4215 9855 | | | | |
| Probal Sen | Oil & Gas | Probal.sen@centrum.co.in | +91-22-4215 9001 | | | | |
| Cyndrella Carvalho | Pharma | cyndrella.carvalho@centrum.co.in | +91-22-4215 9643 | | | | |
| Sparsh Chhabra | Economist | sparsh.chhabra@centrum.co.in | +91-22-4215 9035 | | | | |
| Joaquim Fernandes | Quant | Joaquim.Fernandes@centrum.co.in | +91-22-4215 9363 | | | | |
| Equity Sales | Designation | Email | Phone number | | | | |
| Rajesh Makharia | Director | rajesh.makharia@centrum.co.in | +91-22-4215 9854 | | | | |
| Paresh Shah | MD | paresh.shah@centrum.co.in | +91-22-4215 9617 | | | | |
| Anil Chaurasia | Sr. VP | anil.chaurasia@centrum.co.in | +91-22-4215 9631 | | | | |
| Himani Sanghavi | AVP | himani.sanghavi@centrum.co.in | +91-22-4215 9082 | | | | |
| Saahil Harwani | Associate | saahil.harwani@centrum.co.in | +91-22-4215 9623 | | | | |